What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.
Stocks · News reference
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $22.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.
Wall Street analysts raised targets for PTC, Cloudflare, PENN, Microsoft and others, while downgrading PTC and upgrading PENN and Abbott.
StoneX analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $16 to $20.
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.